<DOC>
	<DOC>NCT00415129</DOC>
	<brief_summary>Based on the results from a previous formulation/dosage ranging trial, this phase II multicenter, open trial was designed to determine the safety and immunogenicity of two vaccine formulation/dosages with and without adjuvant 21 days after each vaccination in adults (18 to 60 years and in the elderly (&gt; 60 years) as required by the European Medicines Agency (EMEA) guideline. The antibody persistence until the booster vaccination at 6 or 12 months will also be evaluated.</brief_summary>
	<brief_title>Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Orthomyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged over 18 years on the day of inclusion Informed consent form signed Able to attend all scheduled visits and to comply with all trial procedures For a woman, inability to bear a child or negative urine pregnancy test For a woman of childbearing potential, use of an effective method of contraception or abstinence for at least 4 weeks prior and at least 4 weeks after to each vaccination. Exclusion Criteria : Systemic hypersensitivity to any component of the vaccine or a lifethreatening reaction after previous administration of a vaccine containing the same substances Febrile illness (oral temperature ≥ 37.5°C) on the day of inclusion Breastfeeding Previous vaccination with an avian flu vaccine Participation in a clinical trial (drug, device, or medical procedure) within 4 weeks prior to the first vaccination Planned participation in another clinical trial during the present trial period Congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy such as anticancer chemotherapy or radiation therapy within the preceding 6 months or longterm systemic corticosteroid therapy Chronic illness that could interfere with trial conduct or completion (e.g. cardiac, renal, diabetes, or autoimmune disorders) Current alcohol or drug abuse that may interfere with the subject's ability to comply with trial procedures Receipt of blood or bloodderived products within the past 3 months Any vaccination within 4 weeks prior to the first trial vaccination Vaccination planned within 4 weeks after any trial vaccination Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Orthomyxoviridae Infections</keyword>
	<keyword>Influenza Pandemics</keyword>
	<keyword>A/H5N1 strain</keyword>
</DOC>